Get informed when a big investor buys or sells
+ FollowOvervalued by 10.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $48.81 Trillion |
|---|---|
| Enterprise Value | $51.60 Trillion |
| Annual dividend | $714.29 |
| Dividend yield | 0.33% |
| Earnings per Share | $4466.05 |
| Beta | 0.32 |
| Outstanding Shares | 243,163,000 |
| P/E Ratio | 37.28 |
|---|---|
| PEG | -48.84 |
| Price to Sales | 9.56 |
| Price to Book Ratio | 2.88 |
| Enterprise Value to Revenue | 9.48 |
| Enterprise Value to EBIT | 29.16 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.22 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Rem...